Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors
Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitini...
Uloženo v:
| Vydáno v: | Clinical cancer research Ročník 22; číslo 12; s. 2897 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
15.06.2016
|
| Témata: | |
| ISSN: | 1078-0432, 1557-3265, 1557-3265 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitinib, a potent oral IGF1R/INSR inhibitor, with EGFR inhibitor erlotinib.
This open-label, dose-escalation study investigated linsitinib schedules S1: once daily intermittent (days 1-3 weekly); S2, once daily continuous; S3, twice-daily continuous; each with erlotinib 100-150 mg once daily; and a non-small cell lung cancer (NSCLC) expansion cohort.
Ninety-five patients were enrolled (S1, 44; S2, 24; S3, 12; expansion cohort, 15) and 91 treated. Seven experienced dose-limiting toxicities: QTc prolongation (3), abnormal liver function (2), hyperglycemia (1), and anorexia (1). Common adverse events included drug eruption (84%), diarrhea (73%), fatigue (68%), nausea (58%), vomiting (40%). MTDs for linsitinib/erlotinib were 450/150 mg (S1), 400/100 mg (S2). On the basis of prior monotherapy data, S3 dosing at 150 mg twice daily/150 mg once daily was the recommended phase II dose for the expansion cohort. There was no evidence of drug-drug interaction. Pharmacodynamic data showed IGF-1 elevation and reduced IGF1R/INSR phosphorylation, suggesting pathway inhibition. Across schedules, 5/75 (7%) evaluable patients experienced partial responses: spinal chordoma (268+ weeks), rectal cancer (36 weeks), three NSCLCs including 2 adenocarcinomas (16, 72 weeks), 1 squamous wild-type EGFR NSCLC (36 weeks). Disease control (CR+PR+SD) occurred in 38 of 75 (51%), and 28 of 91 (31%) patients were on study >12 weeks.
The linsitinib/erlotinib combination was tolerable with preliminary evidence of activity, including durable responses in cases unlikely to respond to erlotinib monotherapy. Clin Cancer Res; 22(12); 2897-907. ©2016 AACR. |
|---|---|
| AbstractList | Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitinib, a potent oral IGF1R/INSR inhibitor, with EGFR inhibitor erlotinib.PURPOSECross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitinib, a potent oral IGF1R/INSR inhibitor, with EGFR inhibitor erlotinib.This open-label, dose-escalation study investigated linsitinib schedules S1: once daily intermittent (days 1-3 weekly); S2, once daily continuous; S3, twice-daily continuous; each with erlotinib 100-150 mg once daily; and a non-small cell lung cancer (NSCLC) expansion cohort.EXPERIMENTAL DESIGNThis open-label, dose-escalation study investigated linsitinib schedules S1: once daily intermittent (days 1-3 weekly); S2, once daily continuous; S3, twice-daily continuous; each with erlotinib 100-150 mg once daily; and a non-small cell lung cancer (NSCLC) expansion cohort.Ninety-five patients were enrolled (S1, 44; S2, 24; S3, 12; expansion cohort, 15) and 91 treated. Seven experienced dose-limiting toxicities: QTc prolongation (3), abnormal liver function (2), hyperglycemia (1), and anorexia (1). Common adverse events included drug eruption (84%), diarrhea (73%), fatigue (68%), nausea (58%), vomiting (40%). MTDs for linsitinib/erlotinib were 450/150 mg (S1), 400/100 mg (S2). On the basis of prior monotherapy data, S3 dosing at 150 mg twice daily/150 mg once daily was the recommended phase II dose for the expansion cohort. There was no evidence of drug-drug interaction. Pharmacodynamic data showed IGF-1 elevation and reduced IGF1R/INSR phosphorylation, suggesting pathway inhibition. Across schedules, 5/75 (7%) evaluable patients experienced partial responses: spinal chordoma (268+ weeks), rectal cancer (36 weeks), three NSCLCs including 2 adenocarcinomas (16, 72 weeks), 1 squamous wild-type EGFR NSCLC (36 weeks). Disease control (CR+PR+SD) occurred in 38 of 75 (51%), and 28 of 91 (31%) patients were on study >12 weeks.RESULTSNinety-five patients were enrolled (S1, 44; S2, 24; S3, 12; expansion cohort, 15) and 91 treated. Seven experienced dose-limiting toxicities: QTc prolongation (3), abnormal liver function (2), hyperglycemia (1), and anorexia (1). Common adverse events included drug eruption (84%), diarrhea (73%), fatigue (68%), nausea (58%), vomiting (40%). MTDs for linsitinib/erlotinib were 450/150 mg (S1), 400/100 mg (S2). On the basis of prior monotherapy data, S3 dosing at 150 mg twice daily/150 mg once daily was the recommended phase II dose for the expansion cohort. There was no evidence of drug-drug interaction. Pharmacodynamic data showed IGF-1 elevation and reduced IGF1R/INSR phosphorylation, suggesting pathway inhibition. Across schedules, 5/75 (7%) evaluable patients experienced partial responses: spinal chordoma (268+ weeks), rectal cancer (36 weeks), three NSCLCs including 2 adenocarcinomas (16, 72 weeks), 1 squamous wild-type EGFR NSCLC (36 weeks). Disease control (CR+PR+SD) occurred in 38 of 75 (51%), and 28 of 91 (31%) patients were on study >12 weeks.The linsitinib/erlotinib combination was tolerable with preliminary evidence of activity, including durable responses in cases unlikely to respond to erlotinib monotherapy. Clin Cancer Res; 22(12); 2897-907. ©2016 AACR.CONCLUSIONSThe linsitinib/erlotinib combination was tolerable with preliminary evidence of activity, including durable responses in cases unlikely to respond to erlotinib monotherapy. Clin Cancer Res; 22(12); 2897-907. ©2016 AACR. Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitinib, a potent oral IGF1R/INSR inhibitor, with EGFR inhibitor erlotinib. This open-label, dose-escalation study investigated linsitinib schedules S1: once daily intermittent (days 1-3 weekly); S2, once daily continuous; S3, twice-daily continuous; each with erlotinib 100-150 mg once daily; and a non-small cell lung cancer (NSCLC) expansion cohort. Ninety-five patients were enrolled (S1, 44; S2, 24; S3, 12; expansion cohort, 15) and 91 treated. Seven experienced dose-limiting toxicities: QTc prolongation (3), abnormal liver function (2), hyperglycemia (1), and anorexia (1). Common adverse events included drug eruption (84%), diarrhea (73%), fatigue (68%), nausea (58%), vomiting (40%). MTDs for linsitinib/erlotinib were 450/150 mg (S1), 400/100 mg (S2). On the basis of prior monotherapy data, S3 dosing at 150 mg twice daily/150 mg once daily was the recommended phase II dose for the expansion cohort. There was no evidence of drug-drug interaction. Pharmacodynamic data showed IGF-1 elevation and reduced IGF1R/INSR phosphorylation, suggesting pathway inhibition. Across schedules, 5/75 (7%) evaluable patients experienced partial responses: spinal chordoma (268+ weeks), rectal cancer (36 weeks), three NSCLCs including 2 adenocarcinomas (16, 72 weeks), 1 squamous wild-type EGFR NSCLC (36 weeks). Disease control (CR+PR+SD) occurred in 38 of 75 (51%), and 28 of 91 (31%) patients were on study >12 weeks. The linsitinib/erlotinib combination was tolerable with preliminary evidence of activity, including durable responses in cases unlikely to respond to erlotinib monotherapy. Clin Cancer Res; 22(12); 2897-907. ©2016 AACR. |
| Author | Poondru, Srinivasu McCarthy, Sean Juergens, Rosalyn A Stephens, Andrew W Gogov, Sven Macaulay, Valentine M Rudin, Charles M Gedrich, Richard Eckhardt, S Gail Gadgeel, Shirish M Middleton, Mark R |
| Author_xml | – sequence: 1 givenname: Valentine M surname: Macaulay fullname: Macaulay, Valentine M email: valentine.macaulay@oncology.ox.ac.uk organization: University Department of Oncology, Oxford Cancer and Haematology Centre, Headington, Oxford, United Kingdom. valentine.macaulay@oncology.ox.ac.uk – sequence: 2 givenname: Mark R surname: Middleton fullname: Middleton, Mark R organization: University Department of Oncology, Oxford Cancer and Haematology Centre, Headington, Oxford, United Kingdom – sequence: 3 givenname: S Gail surname: Eckhardt fullname: Eckhardt, S Gail organization: University of Colorado Cancer Center, Aurora, Colorado – sequence: 4 givenname: Charles M surname: Rudin fullname: Rudin, Charles M organization: Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 5 givenname: Rosalyn A surname: Juergens fullname: Juergens, Rosalyn A organization: Juravinski Cancer Centre McMaster University, Hamilton, Ontario, Canada – sequence: 6 givenname: Richard surname: Gedrich fullname: Gedrich, Richard organization: Kolltan Pharmaceuticals, Inc, New Haven, Connecticut – sequence: 7 givenname: Sven surname: Gogov fullname: Gogov, Sven organization: Novartis Pharma AG, Basel, Switzerland – sequence: 8 givenname: Sean surname: McCarthy fullname: McCarthy, Sean organization: Finell Clinical Ltd, London, United Kingdom – sequence: 9 givenname: Srinivasu surname: Poondru fullname: Poondru, Srinivasu organization: Astellas Pharma Global Development, Northbrook, Illinois – sequence: 10 givenname: Andrew W surname: Stephens fullname: Stephens, Andrew W organization: Piramal Imaging GmbH, Berlin, Germany – sequence: 11 givenname: Shirish M surname: Gadgeel fullname: Gadgeel, Shirish M organization: Karmanos Cancer Institute/Wayne State University, Detroit, Michigan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26831715$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kE9PwjAAxRujkT_6ETQ94qHYdu3aHslEJSGBCJ6Xbu1Cydbiumn49pIAp_fy8nvv8Ebg1gdvAXgieEoIl68EC4kwS-g0y74Q4YhSIm_AkHAuUEJTfnvyV2YARjHuMSaMYHYPBjSVCRGED8F-vdPRwgV8C9GieSx1rTsXPNx0vTnCUMGl89F1zrsCTlabBVI4fYHaGzhv63DOnYfrU8v6LsI_1-3gzPxqX1oDN6F2Bm77JrTxAdxVuo728aJj8P0-32afaLn6WGSzJSoZYx2SQhQCS51UTEmGS0WVLURFdVUIhY2UMlGGE44LpkxSJilXulIV1hUm1haajsHkvHtow09vY5c3Lpa2rrW3oY85EUpIkXJMT-jzBe2Lxpr80LpGt8f8-g_9Bz6aaMI |
| CitedBy_id | crossref_primary_10_1016_j_jhepr_2025_101475 crossref_primary_10_1200_JCO_2016_68_9349 crossref_primary_10_3390_life12121992 crossref_primary_10_3389_fendo_2023_1142644 crossref_primary_10_3389_fneur_2020_00657 crossref_primary_10_1136_jitc_2021_002722 crossref_primary_10_1007_s11523_021_00814_5 crossref_primary_10_3389_fonc_2019_00030 crossref_primary_10_3390_ijms22020813 crossref_primary_10_1016_j_path_2017_04_008 crossref_primary_10_4103_tcmj_tcmj_288_24 crossref_primary_10_3389_fonc_2022_941046 crossref_primary_10_3390_ijms26115204 crossref_primary_10_1177_10781552251327598 crossref_primary_10_3389_fonc_2018_00202 crossref_primary_10_1158_0008_5472_CAN_22_3059 crossref_primary_10_1080_17568919_2025_2470105 crossref_primary_10_3389_fonc_2016_00098 crossref_primary_10_1016_j_cllc_2016_07_007 crossref_primary_10_1016_j_cllc_2024_02_005 crossref_primary_10_1038_bjc_2017_226 crossref_primary_10_1080_13543784_2019_1694660 crossref_primary_10_2174_1381612828666220608122934 crossref_primary_10_3389_fendo_2021_688104 crossref_primary_10_1002_path_5739 crossref_primary_10_1016_j_mrrev_2016_09_005 crossref_primary_10_1007_s11523_017_0514_5 crossref_primary_10_3389_fonc_2022_1055589 crossref_primary_10_3390_cells8080895 crossref_primary_10_3390_cancers12123717 crossref_primary_10_3390_cells10061483 crossref_primary_10_3390_cells10092320 crossref_primary_10_1002_adtp_202400137 crossref_primary_10_1016_j_mce_2020_111003 crossref_primary_10_1016_j_ygyno_2018_01_019 crossref_primary_10_3390_cancers13236072 crossref_primary_10_15252_msb_202110239 crossref_primary_10_3390_pharmaceutics15041274 crossref_primary_10_1016_j_colsurfb_2022_112366 crossref_primary_10_3390_cancers15174252 crossref_primary_10_1038_s41598_022_15552_5 |
| ContentType | Journal Article |
| Copyright | 2016 American Association for Cancer Research. |
| Copyright_xml | – notice: 2016 American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1078-0432.CCR-15-2218 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-3265 |
| ExternalDocumentID | 26831715 |
| Genre | Multicenter Study Journal Article Clinical Trial, Phase I |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO NPM OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV 7X8 |
| ID | FETCH-LOGICAL-c444t-877b708a3f49840c929eb7f2afb790d88839d5150b49d3c3659af9f0af01eeba2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 55 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000377958800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1078-0432 1557-3265 |
| IngestDate | Fri Sep 05 07:14:19 EDT 2025 Mon Jul 21 05:53:41 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | 2016 American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c444t-877b708a3f49840c929eb7f2afb790d88839d5150b49d3c3659af9f0af01eeba2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://clincancerres.aacrjournals.org/content/clincanres/22/12/2897.full.pdf |
| PMID | 26831715 |
| PQID | 1797876502 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1797876502 pubmed_primary_26831715 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-06-15 |
| PublicationDateYYYYMMDD | 2016-06-15 |
| PublicationDate_xml | – month: 06 year: 2016 text: 2016-06-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical cancer research |
| PublicationTitleAlternate | Clin Cancer Res |
| PublicationYear | 2016 |
| References | 17671083 - Mol Cancer Ther. 2007 Aug;6(8):2158-67 22237261 - J Thorac Oncol. 2012 Feb;7(2):419-26 21425998 - Future Med Chem. 2009 Sep;1(6):1153-71 24045151 - J Hepatol. 2014 Feb;60(2):319-24 23454899 - Cancer Discov. 2013 May;3(5):548-63 16890575 - Clin Pharmacol Ther. 2006 Aug;80(2):136-45 19754359 - Curr Cancer Drug Targets. 2009 Sep;9(6):748-60 25979928 - Clin Cancer Res. 2015 May 15;21(10):2221-6 24033707 - Br J Clin Pharmacol. 2014 Jun;77(6):917-28 15987464 - Breast Cancer Res. 2005;7(4):R570-9 17664484 - J Clin Oncol. 2007 Aug 1;25(22):3362-71 24485233 - Clin Lung Cancer. 2014 May;15(3):213-21 20924128 - Mol Cancer Ther. 2010 Oct;9(10):2652-64 25896444 - Carcinogenesis. 2015 Jun;36(6):648-55 25123819 - Cancer Treat Rev. 2014 Oct;40(9):1096-105 25309870 - Front Oncol. 2014 Sep 15;4:244 22025157 - J Clin Oncol. 2011 Dec 1;29(34):4574-80 20457905 - Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791-8 22359227 - Cancer. 2012 Aug 15;118(16):3993-4003 11432895 - J Clin Oncol. 2001 Jul 1;19(13):3267-79 16819546 - Br J Cancer. 2006 Jul 17;95(2):172-80 14682118 - Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):11-6 12203212 - Hum Pathol. 2002 Aug;33(8):801-5 25168481 - Cancer Res. 2014 Oct 15;74(20):5866-77 24797726 - Cancer. 2014 Aug 15;120(16):2448-56 22508822 - J Clin Oncol. 2012 May 20;30(15):1849-56 22977626 - Exp Ther Med. 2011 Nov;2(6):1091-1095 19752219 - Endocr Rev. 2009 Oct;30(6):586-623 25212606 - Clin Cancer Res. 2015 Feb 15;21(4):701-11 25335932 - Invest New Drugs. 2015 Feb;33(1):187-93 25208878 - Clin Cancer Res. 2015 Feb 15;21(4):693-700 19097774 - Eur J Cancer. 2009 Jan;45(2):228-47 22215692 - Cancer Res. 2012 Jan 1;72(1):3-12 23515613 - Mol Cancer Ther. 2013 Jun;12(6):1131-9 24439931 - Lancet Oncol. 2014 Feb;15(2):191-200 25632036 - Sci Transl Med. 2015 Jan 28;7(272):272ra12 25886138 - BMC Cancer. 2015 Apr 04;15:223 25566194 - Front Endocrinol (Lausanne). 2014 Dec 23;5:224 22337149 - Nat Rev Cancer. 2012 Feb 16;12(3):159-69 23531874 - Oncotarget. 2013 Mar;4(3):463-73 22025154 - J Clin Oncol. 2011 Dec 1;29(34):4534-40 24458568 - Int J Cancer. 2014 Aug 15;135(4):1002-6 21139139 - Sci Signal. 2010 Dec 07;3(151):ra87 15728811 - N Engl J Med. 2005 Feb 24;352(8):786-92 18927274 - Clin Cancer Res. 2008 Oct 15;14(20):6364-70 25795408 - Lancet Oncol. 2015 Apr;16(4):426-35 17914107 - Endocr Relat Cancer. 2007 Sep;14(3):781-90 23572164 - Endocr Relat Cancer. 2013 May 21;20(3):383-90 25781862 - Cancer. 2015 Jun 15;121(12 ):2078-82 15118125 - Science. 2004 Jun 4;304(5676):1497-500 |
| References_xml | – reference: 11432895 - J Clin Oncol. 2001 Jul 1;19(13):3267-79 – reference: 24033707 - Br J Clin Pharmacol. 2014 Jun;77(6):917-28 – reference: 21139139 - Sci Signal. 2010 Dec 07;3(151):ra87 – reference: 24439931 - Lancet Oncol. 2014 Feb;15(2):191-200 – reference: 17671083 - Mol Cancer Ther. 2007 Aug;6(8):2158-67 – reference: 25781862 - Cancer. 2015 Jun 15;121(12 ):2078-82 – reference: 23531874 - Oncotarget. 2013 Mar;4(3):463-73 – reference: 18927274 - Clin Cancer Res. 2008 Oct 15;14(20):6364-70 – reference: 19097774 - Eur J Cancer. 2009 Jan;45(2):228-47 – reference: 17664484 - J Clin Oncol. 2007 Aug 1;25(22):3362-71 – reference: 25795408 - Lancet Oncol. 2015 Apr;16(4):426-35 – reference: 14682118 - Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):11-6 – reference: 25309870 - Front Oncol. 2014 Sep 15;4:244 – reference: 23515613 - Mol Cancer Ther. 2013 Jun;12(6):1131-9 – reference: 25123819 - Cancer Treat Rev. 2014 Oct;40(9):1096-105 – reference: 25886138 - BMC Cancer. 2015 Apr 04;15:223 – reference: 22977626 - Exp Ther Med. 2011 Nov;2(6):1091-1095 – reference: 17914107 - Endocr Relat Cancer. 2007 Sep;14(3):781-90 – reference: 15728811 - N Engl J Med. 2005 Feb 24;352(8):786-92 – reference: 16819546 - Br J Cancer. 2006 Jul 17;95(2):172-80 – reference: 12203212 - Hum Pathol. 2002 Aug;33(8):801-5 – reference: 15987464 - Breast Cancer Res. 2005;7(4):R570-9 – reference: 22359227 - Cancer. 2012 Aug 15;118(16):3993-4003 – reference: 16890575 - Clin Pharmacol Ther. 2006 Aug;80(2):136-45 – reference: 20924128 - Mol Cancer Ther. 2010 Oct;9(10):2652-64 – reference: 22025157 - J Clin Oncol. 2011 Dec 1;29(34):4574-80 – reference: 24485233 - Clin Lung Cancer. 2014 May;15(3):213-21 – reference: 24458568 - Int J Cancer. 2014 Aug 15;135(4):1002-6 – reference: 15118125 - Science. 2004 Jun 4;304(5676):1497-500 – reference: 23572164 - Endocr Relat Cancer. 2013 May 21;20(3):383-90 – reference: 22215692 - Cancer Res. 2012 Jan 1;72(1):3-12 – reference: 23454899 - Cancer Discov. 2013 May;3(5):548-63 – reference: 25212606 - Clin Cancer Res. 2015 Feb 15;21(4):701-11 – reference: 25979928 - Clin Cancer Res. 2015 May 15;21(10):2221-6 – reference: 25208878 - Clin Cancer Res. 2015 Feb 15;21(4):693-700 – reference: 22337149 - Nat Rev Cancer. 2012 Feb 16;12(3):159-69 – reference: 22508822 - J Clin Oncol. 2012 May 20;30(15):1849-56 – reference: 25335932 - Invest New Drugs. 2015 Feb;33(1):187-93 – reference: 25896444 - Carcinogenesis. 2015 Jun;36(6):648-55 – reference: 25632036 - Sci Transl Med. 2015 Jan 28;7(272):272ra12 – reference: 19752219 - Endocr Rev. 2009 Oct;30(6):586-623 – reference: 25168481 - Cancer Res. 2014 Oct 15;74(20):5866-77 – reference: 19754359 - Curr Cancer Drug Targets. 2009 Sep;9(6):748-60 – reference: 24797726 - Cancer. 2014 Aug 15;120(16):2448-56 – reference: 25566194 - Front Endocrinol (Lausanne). 2014 Dec 23;5:224 – reference: 22025154 - J Clin Oncol. 2011 Dec 1;29(34):4534-40 – reference: 21425998 - Future Med Chem. 2009 Sep;1(6):1153-71 – reference: 22237261 - J Thorac Oncol. 2012 Feb;7(2):419-26 – reference: 24045151 - J Hepatol. 2014 Feb;60(2):319-24 – reference: 20457905 - Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791-8 |
| SSID | ssj0014104 |
| Score | 2.4333885 |
| Snippet | Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2897 |
| SubjectTerms | Adult Aged Aged, 80 and over Antigens, CD Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Dose-Response Relationship, Drug Erlotinib Hydrochloride - adverse effects Erlotinib Hydrochloride - pharmacokinetics Erlotinib Hydrochloride - therapeutic use Female Humans Imidazoles - adverse effects Imidazoles - pharmacokinetics Imidazoles - therapeutic use Lung Neoplasms - drug therapy Male Maximum Tolerated Dose Middle Aged Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazines - adverse effects Pyrazines - pharmacokinetics Pyrazines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Insulin - antagonists & inhibitors Receptors, Somatomedin - antagonists & inhibitors Young Adult |
| Title | Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26831715 https://www.proquest.com/docview/1797876502 |
| Volume | 22 |
| WOSCitedRecordID | wos000377958800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--H-uLCB70EG3TNGlPIuuKe9i1-IC9lSRNsLK2ul0F_72TtuJJEKTQQ6FQMl9mvsl8nUHomGnuBmwLYpSSBBixIjIMnMrcZCE3kbFU1sMmxHAYjUZx0h64Va2s8tsn1o46K7U7Iz8H4AC2gE_Qi9c34qZGuepqO0JjFs0HQGUcqsXop4rA_Hp8IIRM2EiUh-0fPH4YgbNwnWVZQM-63Tvih4RSP_qdZdbR5nrlv9-5ipZbnokvG2CsoRlTrKPFQVtJ30DPyRPEL9zHV2VlSK8CU9U2wk5Y-IlLiyFLdXquIlf45Pa-T2KPn2JZZLg3GZfN87zASdOXtcLuQBdftooCfF-O8ww_vL-Uk2oTPV73Hro3pJ27QDRjbAoOUijhRTKwLIb8TwODMkqA0awSsZdBzhzEGRjYUyzOAh3wMJY2tp60nm-MknQLzRVlYXYQthHngIJARDJjWgq4XA7GhTaaSuV30NH3KqaAa1eskIUp36v0Zx07aLsxRfraNOBIKY-A9vjh7h_e3kNLwHG4U3f54T6at7CrzQFa0B_TvJoc1oCB-zAZfAGo5MjD |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+I+Dose-Escalation+Study+of+Linsitinib+%28OSI-906%29+and+Erlotinib+in+Patients+with+Advanced+Solid+Tumors&rft.jtitle=Clinical+cancer+research&rft.au=Macaulay%2C+Valentine+M&rft.au=Middleton%2C+Mark+R&rft.au=Eckhardt%2C+S+Gail&rft.au=Rudin%2C+Charles+M&rft.date=2016-06-15&rft.issn=1078-0432&rft.volume=22&rft.issue=12&rft.spage=2897&rft_id=info:doi/10.1158%2F1078-0432.CCR-15-2218&rft_id=info%3Apmid%2F26831715&rft_id=info%3Apmid%2F26831715&rft.externalDocID=26831715 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |